“…Tocilizumab Acharya et al [ 21 ] | 5 | 59/F | HTN Hyperuricemia | Pneumonia, ARF | 10th day of ICU (Dx at OPD) | CRAO (OS) | D-dimer, fibrinogen, CRP, IL-1 RA, IL-6, IL-7 | Unremarkable – Brain CTA, MR | OCT, FP, FA | HCQ, Lopinavir/Ritonavir, Tocilizumab | Montesel et al [ 22 ] |
6 | 48/M | Obesity, Sleep disorder | Pneumonia → septic shock, dCMP, ARF, Fungemia | 6th week of hosp. (24 h after apixaban change) | OAO (OD) | Pro-calcitonin, ferritin, fibrinogen, D-dimer | Unremarkable – Brain MR, Orbit MR, Head and neck CT, Echo | Fundoscopy | HCQ, Tocilizumab, Enoxaparin to Apixaban | Dumitrascu et al [ 23 ] |
7 | 65/F | None but obese | Mild disease → no admission | 5 weeks after COVID-19 Dx | BRAO (OS) | D-dimer | Unremarkable – Echo | Fundoscopy | Favipiravir | Uzun et al [ 24 ] |
8 | 54/M | None | Fever, anosmia, cough → no admission | 3 weeks after COVID-19 Dx | CRAO (OD) | D-dimer, CRP, ferritin, platelet, fibrinogen | Unremarkable – Brain MR, Carotid US | FP, OCT, FA | HCQ, Azithromycin, Favipiravir, Enoxaparin | Ucar et al [ 25 ] |
9 | 54/M | None | Mild myalgia, fever |
…”